Frontiers in Pharmacology (Jul 2018)

In Vivo Non-radioactive Assessment of mGlu5 Receptor-Activated Polyphosphoinositide Hydrolysis in Response to Systemic Administration of a Positive Allosteric Modulator

  • Anna R. Zuena,
  • Luisa Iacovelli,
  • Rosamaria Orlando,
  • Luisa Di Menna,
  • Paola Casolini,
  • Giovanni Sebastiano Alemà,
  • Gabriele Di Cicco,
  • Giuseppe Battaglia,
  • Ferdinando Nicoletti,
  • Ferdinando Nicoletti

DOI
https://doi.org/10.3389/fphar.2018.00804
Journal volume & issue
Vol. 9

Abstract

Read online

mGlu5 receptor-mediated polyphosphoinositide (PI) hydrolysis is classically measured by determining the amount of radioactivity incorporated in inositolmonophosphate (InsP) after labeling of membrane phospholipids with radioactive inositol. Although this method is historically linked to the study of mGlu receptors, it is inappropriate for the assessment of mGlu5 receptor signaling in vivo. Using a new ELISA kit we showed that systemic treatment with the selective positive allosteric modulator (PAM) of mGlu5 receptors VU0360172 enhanced InsP formation in different brain regions of CD1 or C57Black mice. The action of VU0360172 was sensitive to the mGlu5 receptor, negative allosteric modulator (NAM), MTEP, and was abolished in mice lacking mGlu5 receptors. In addition, we could demonstrate that endogenous activation of mGlu5 receptors largely accounted for the basal PI hydrolysis particularly in the prefrontal cortex. This method offers opportunity for investigation of mGlu5 receptor signaling in physiology and pathology, and could be used for the functional screening of mGlu5 receptor PAMs in living animals.

Keywords